PROGRAM SYMPOSIUM AND PRESENTATION FILES
WHO-ILAR COPCORD Stage II Education on Treatment of
Autoimmune Diseases, a One-day International Symposium,
Saturday, May 21, 2005, JW Marriott Hotel, Jakarta,
Indonesia”
Breakthrough in the Treatment of Lupus Nephritis and RF+
RA – Achievements of Remission with Intravenous Therapy
after 2-4 months, Remission with Oral Drugs after
5.5-7.5 months, and Remission without Drug after
3.5.-4.5 years treatment.
|
09.30-09.45 |
Welcome by Prof. Remy A Nasution,
President of the WHO-ILAR COPCORD Stage II
International Symposium Education on Treatment
of Autoimmune Disease
|
|
Morning Session |
Breakthrough in the Treatment of Lupus
Nephritis–Remission with Intravenous Therapy
after 2-4 months
|
|
Chairman |
Prof. A Remy Nasution, Jakarta, Indonesia |
|
Co-Chairman |
Adiwirawan Mardjuadi, MD, PhD, Jakarta,
Indonesia Review of the history of the
Outcome of the Therapy of Lupus Nephritis
John Darmawan, MD, PhD, Semarang, Indonesia
Download slide presentation
Outcome of Lupus Nephritis after Therapy
with the SBP-5-IMNs
Dr. Tran Thi Minth Hoa, Hanoi, Vietnam
Download slide presentation
Seven-years Outcome of Lupus Nephritis
After Treatment with the SBP-5-IMNs
John Darmawan, MD, PhD, Semarang, Indonesia
Download slide presentation
Outcome of Lupus Nephritis After Treatment
with the SBP-5-IMNs
Prof. Zhao Dongbao, Shanghai, China (Absent, it
was presented by John Darmawan, MD, PhD.)
Download slide presentation
Summary
John Darmawan, MD, PhD, Semarang, Indonesia
|
|
10.45-11.15 |
Coffee Break
Breakthrough in the Treatment of RF+ RA –
Remission under Intravenous Therapy after 2-4
months
|
|
Chairman |
Prof. Johannes J Rasker, Enschede, The
Netherlands
|
|
Co-Chairman |
Adiwirawan Mardjuadi, MD, PhD, Jakarta,
Indonesia |
|
|
Review of the history of the Outcome of
treatment of RF+ RA
Prof. Johannes J Rasker, Enschede, The
Netherlands
Download slide presentation
Seven-years Outcome of RF+ RA After
Treatment with the SBP-5-IMNs
John Darmawan, MD, PhD, Semarang, Indonesia
Download slide presentation
Outcome of RF+ RA after Treatment with the
SBP-5-IMNs
Prof. Syed Atigul Haq, Dacca, Bangladesh
Download slide presentation
Outcome of RF+ RA by the SBP-6-IMNs
Dr. Soosan Soorosh, Teheran, Iran
Download slide presentation
Outcome of RF+ RA After Treatment with the
SBP-5-IMNs
Prof. Zhao Dongbao, Shanghai, China
Download slide presentation
Summary
Prof. Johannes J Rasker, Enschede, The
Netherlands
Download slide presentation
|
|
Panel Discussion |
Questions from the audience and Answers by the
Panelists on The SBP-5-IMNs and SBP-6-IMNs in
terms of efficacy, adverse effects, and
cost-effectiveness.
|
|
Panelist |
John Darmawan, MD, PhD, Prof. Johannes J Rasker,
and Prof. Remy A Nasution Prof Syed atigul Haq
|
|
Closing By the protocol |
|
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|
